Piśmiennictwo
1. WHO. World Health Organization; Geneva: 2017. Depression: fact sheet. https://www.who.int/mediacentre/factsheets/fs369/enhttp://www.who.int/mediacentre/facts (accessed Sept 21, 2017). [Google Scholar]
2. NIK. Najwyższa Izba Kontroli LWR.430.001. 2018. Zapobieganie i leczenie depresji. Informacja o wynikach kontroli NIK. https:// www.nik.gov.pl/plik/id,18092,vp,20684
3. Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health 2013;34:119-38
4. Shinohara K, Efthimiou O, Ostinelli EG et al. Comparative efficacy and acceptability of antidepressants in the long-term treatment of major depression: protocol for a systematic review and network meta-analysis BMJ Open 2019;9(5):e027574. doi: 10.1136/bmjopen-2018-027574
5. Gałecki P, Bliźniewska-Kowalska K. Depresja oporna na leczenie – zalecenia Konsultanta Krajowego w dziedzinie psychiatrii. Psychiatr Pol 2019;158:1-15. https://doi.org/10.12740/PP/OnlineFirst/115208
6. Gałecki P. Recommendations of the national consultant in the field of psychiatry for the treatment of depressive episode and recurrent depressive disorders. Pharmacotherapy in Psychiatry and Neurology 2018;34(3). http://dx.medra.org/10.17393/fpn.2018.11.001
7. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple treatments meta-analysis. Lancet 2009;373:746-58
8. Cipriani A, Furukawa TA, Salanti G et al. Comparative efficacy and acceptability of 21 antidepressant drug for the acute treatment of adults with major depressive disorder: a systematic review and Network meta-analisis. Lancet 2018;391(10128):1357-66. doi: 10.1016/SO140-6736(17)32802-32807
9. Cipriani A, Zho X, Del Giovane C et al. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 2016;388(10047):881-90. doi: 10.1016/S0140-6736(16)30385-3
10. Samochowiec J, Rybakowski J, Gałecki P et al. Rekomendacje Polskiego Towarzystwa Psychiatrycznego dotyczące leczenia zaburzeń afektywnych u kobiet w wieku rozrodczym. Część I: Leczenie depresji. Psychiatr Pol 2019; 53(2):245-62
11. Osório F de L, Sanches RF, Macedo LR et al. Antidepressant effects of a single dose ayahuasca in patients with recurrent depression: a preliminary report. Rev Bras Psiquiatr 2015;37(1):13-20
12. Palhano-Fontes F, Barreto D, Onias H et al. Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 2018;15:1-9
13. Julk S, Murray C, Wieczorek A, Griffiths H et al. Exploring patients' and carers' views about the clinical use of ketamine to inform policy and practical decisions: mixed-methods study BJPsych Open 2019;5(5):e62. doi: 10.1192/bjo.2019.52
14. Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: A systematic review. J Affect Disord 2019;258:11-24
15. Gartlehner G, Wagner G, Matayas N et al. Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews. BMJ Open 2017;7(6):e014912. doi: 10.1136/bmjopen-2016-014912
16. Haller H, Anheyer D, Cramer H et al. Complementary therapies for clinical depression: an overview of systematic reviews. BMJ Open 2019;9(8):e028527. doi: 10.1136/bmjopen-2018-028527
17. Herman A. Zastosowanie suplementacji probiotykami w profilaktyce i leczeniu zaburzeń depresyjnych i lękowych – przegląd dotychczasowych badań. Psychiatr Pol 2019;53(2):459-73
18. Li H, Sun D, Wang A et al. Serum 25-hydroxyvitamin D levels and depression in older adults: a dose-response meta-analysis of prospective cohort studies. Am J Geriatr Psychiatry 2019;27(11):1192-202
19. Sackeim HA, Devanand DP, Nobler MS. Electroconvulsive therapy. In: Bloom F, Kupfer D, editors. Psychopharmacology: The fourth generation of progress. Raven, New York 1995: 1123-42
20. Aaronson ST, Sears P, Ruvuna F et al. A 5-year observational study of patients with treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am J Psychiatry 2017;174(7):640-8
21. Kedzior K, Azorina V, Reitz SK. More female patients and fewer stimuli per session are associated with the short-term antidepressant properties of repetitive transcranial magnetic stimulation (rTMS): a meta-analysis of 54 sham-controlled studies published between 1997–2013. Neuropsychiatr Dis Treat 2014;10:727-56